标签归档：mutant

Mutant p53 modulator-1

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant p53 modulator-1 

Mutant p53 modulator-1 是一种突变型 p53 调节剂。Mutant p53 modulator-1 可减少含有 p53 突变的癌症的进展 (摘自专利 WO2021231474A1，化合物 231B)。

Mutant p53 modulator-1

Mutant p53 modulator-1 Chemical Structure

CAS No. : 2746371-35-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B)[1].

分子量

576.59

Formula

C27H32F4N8O2
CAS 号

2746371-35-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Binh Vu, et al. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION. Patent WO2021231474A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant IDH1 inhibitor

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant IDH1 inhibitor  纯度: 98.69%

Mutant IDH1 inhibitor 是一个有效的突变型 IDH1 R132H 的抑制剂，IC50 值小于 72 nM。

Mutant IDH1 inhibitor

Mutant IDH1 inhibitor Chemical Structure

CAS No. : 1429180-08-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥2260 In-stock
5 mg ￥2050 In-stock
10 mg ￥3500 In-stock
50 mg ￥10500 In-stock
100 mg ￥18000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Mutant IDH1 inhibitor 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Mitochondria-Targeted Compound Library
  • Glucose Metabolism Compound Library

生物活性

Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.

IC50 & Target

IC50: < 72 nM (mutant IDH1 R132H)
体外研究
(In Vitro)

Mutant IDH1 inhibitor is a potent IDH1 R132H inhibitor, and used for the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

466.58

Formula

C25H34N6O3
CAS 号

1429180-08-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 34 mg/mL (72.87 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1433 mL 10.7163 mL 21.4326 mL
5 mM 0.4287 mL 2.1433 mL 4.2865 mL
10 mM 0.2143 mL 1.0716 mL 2.1433 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH and their preparation. Patent WO 2013046136 A1 20130404
Cell Assay
[1]

Day 1: cells are seeded in 384-well plates in triplicates for both the cell proliferation and 2HG assay, and incubated at 37°C, 95% Rh, 5% CO2 overnight. Day 2: compounds are serially diluted 1 :3 (10 point dilution from 10 mM solutions in DMSO) and delivered to the cell assay plates via acoustic dispenser, with final concentration ranging from 30 μM to 1.5 nM. The plates are returned to the incubator after treatment and incubated for 48 hours. Day 4 Proliferation assay: CTG is added to the assay plates and luminescence signal is read on the plate reader. Day 4 2HG assay : Extraction sample preparation consisted of aspirating all media from the assay plates, adding 70 μL of 90% methanol in water, dry ice incubation for 15 minutes, centrifuging at 2000 rpm for 30 min to ensure all particulates have settled, and transferring 30 μL of the supernatant into LC-MS ready plates. LC-MS analysis follows.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH and their preparation. Patent WO 2013046136 A1 20130404

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant IDH1-IN-2

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant IDH1-IN-2  纯度: 98.50%

Mutant IDH1-IN-2是一种突变型异柠檬酸脱氢酶 (IDH) 蛋白抑制剂, 在LS-MS生物化学检测中IC50值为＜22 nM, 荧光生物化学检测中IC50值为16.6 nM。

Mutant IDH1-IN-2

Mutant IDH1-IN-2 Chemical Structure

CAS No. : 1429176-69-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3030 In-stock
5 mg ￥3000 In-stock
10 mg ￥5000 In-stock
25 mg ￥9500 In-stock
50 mg ￥15500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Mutant IDH1-IN-2 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Mitochondria-Targeted Compound Library
  • Glucose Metabolism Compound Library
  • Targeted Diversity Library

生物活性

Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay. Target: Mutant IDH1 Mutant IDH1-IN-2 has a neomorphic activity and in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer. More bioactivity information in Patent WO 2013046136A1 (Example 224).

分子量

459.53

Formula

C24H31F2N5O2
CAS 号

1429176-69-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (108.81 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1761 mL 10.8807 mL 21.7614 mL
5 mM 0.4352 mL 2.1761 mL 4.3523 mL
10 mM 0.2176 mL 1.0881 mL 2.1761 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.44 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.44 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Huangshu, et al. 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH and their preparation

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant IDH1-IN-6

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant IDH1-IN-6 

Mutant IDH1-IN-6 是一种有效的选择性的具有口服活性的突变型 IDH 抑制剂，对 IDH1 R132H，IDH1 R132C，IDH2 R140Q 和 IDH2 R172K 突变酶的 IC50 分别为 6.27 nM，3.71 nM，36.9 nM 和 11.5 nM。Mutant IDH1-IN-6 抑制 IDH 野生型酶的活性较低。

Mutant IDH1-IN-6

Mutant IDH1-IN-6 Chemical Structure

CAS No. : 2230263-60-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes[1].

IC50 & Target

IC50: 6.27 nM (IDH1 R132H), 3.71 nM (IDH1 R132C), 36.9 nM (IDH2 R140Q), 11.5 nM (IDH2 R172K), 105 nM (IDH1 wild-type) and 884 nM (IDH2 wild-type)[1]
体外研究
(In Vitro)

Mutant IDH1-IN-6 (example 2) inhibits production of 2-hydroxyglutarate in HT1080 cells with an IC50 of 1.28 nM, indicating the inhibition of mutant IDHl R132C in cells. aKG, a metabolite generated by wild-type IDHl is not affected by Mutant IDH1-IN-6, indicating Mutant IDH1-IN-6 is selective for mutant IDHl over wild type IDHl in cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Mutant IDH1-IN-6 (Example 2; 0-32 mg/kg; oral gavage; twice daily; for 3 days) treatment inhibitis of 2-hydroxyglutarate in a dose-dependent manner in IDHl mutant xenograft mice[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic nude mice (20-22 g) injected with TB08 cells[1]
Dosage: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 16 mg/kg, 32 mg/kg
Administration: Oral gavage; twice daily; for 3 days
Result: Inhibitied of 2-hydroxyglutarate in IDHl mutant xenograft mice.

分子量

504.62

Formula

C28H36N6O3
CAS 号

2230263-60-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Renato Alejandro BAUER, et al. 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors. WO2018111707A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant IDH1-IN-6

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant IDH1-IN-6 

Mutant IDH1-IN-6 是一种有效的选择性的具有口服活性的突变型 IDH 抑制剂，对 IDH1 R132H，IDH1 R132C，IDH2 R140Q 和 IDH2 R172K 突变酶的 IC50 分别为 6.27 nM，3.71 nM，36.9 nM 和 11.5 nM。Mutant IDH1-IN-6 抑制 IDH 野生型酶的活性较低。

Mutant IDH1-IN-6

Mutant IDH1-IN-6 Chemical Structure

CAS No. : 2230263-60-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes[1].

IC50 & Target

IC50: 6.27 nM (IDH1 R132H), 3.71 nM (IDH1 R132C), 36.9 nM (IDH2 R140Q), 11.5 nM (IDH2 R172K), 105 nM (IDH1 wild-type) and 884 nM (IDH2 wild-type)[1]
体外研究
(In Vitro)

Mutant IDH1-IN-6 (example 2) inhibits production of 2-hydroxyglutarate in HT1080 cells with an IC50 of 1.28 nM, indicating the inhibition of mutant IDHl R132C in cells. aKG, a metabolite generated by wild-type IDHl is not affected by Mutant IDH1-IN-6, indicating Mutant IDH1-IN-6 is selective for mutant IDHl over wild type IDHl in cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Mutant IDH1-IN-6 (Example 2; 0-32 mg/kg; oral gavage; twice daily; for 3 days) treatment inhibitis of 2-hydroxyglutarate in a dose-dependent manner in IDHl mutant xenograft mice[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic nude mice (20-22 g) injected with TB08 cells[1]
Dosage: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 16 mg/kg, 32 mg/kg
Administration: Oral gavage; twice daily; for 3 days
Result: Inhibitied of 2-hydroxyglutarate in IDHl mutant xenograft mice.

分子量

504.62

Formula

C28H36N6O3
CAS 号

2230263-60-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Renato Alejandro BAUER, et al. 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors. WO2018111707A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant IDH1-IN-6

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant IDH1-IN-6 

Mutant IDH1-IN-6 是一种有效的选择性的具有口服活性的突变型 IDH 抑制剂，对 IDH1 R132H，IDH1 R132C，IDH2 R140Q 和 IDH2 R172K 突变酶的 IC50 分别为 6.27 nM，3.71 nM，36.9 nM 和 11.5 nM。Mutant IDH1-IN-6 抑制 IDH 野生型酶的活性较低。

Mutant IDH1-IN-6

Mutant IDH1-IN-6 Chemical Structure

CAS No. : 2230263-60-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes[1].

IC50 & Target

IC50: 6.27 nM (IDH1 R132H), 3.71 nM (IDH1 R132C), 36.9 nM (IDH2 R140Q), 11.5 nM (IDH2 R172K), 105 nM (IDH1 wild-type) and 884 nM (IDH2 wild-type)[1]
体外研究
(In Vitro)

Mutant IDH1-IN-6 (example 2) inhibits production of 2-hydroxyglutarate in HT1080 cells with an IC50 of 1.28 nM, indicating the inhibition of mutant IDHl R132C in cells. aKG, a metabolite generated by wild-type IDHl is not affected by Mutant IDH1-IN-6, indicating Mutant IDH1-IN-6 is selective for mutant IDHl over wild type IDHl in cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Mutant IDH1-IN-6 (Example 2; 0-32 mg/kg; oral gavage; twice daily; for 3 days) treatment inhibitis of 2-hydroxyglutarate in a dose-dependent manner in IDHl mutant xenograft mice[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic nude mice (20-22 g) injected with TB08 cells[1]
Dosage: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 16 mg/kg, 32 mg/kg
Administration: Oral gavage; twice daily; for 3 days
Result: Inhibitied of 2-hydroxyglutarate in IDHl mutant xenograft mice.

分子量

504.62

Formula

C28H36N6O3
CAS 号

2230263-60-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Renato Alejandro BAUER, et al. 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors. WO2018111707A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant IDH1-IN-4

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant IDH1-IN-4  纯度: ≥99.0%

Mutant IDH1-IN-4 (compound 434) 是一种突变型异柠檬酸脱氢酶 1 (IDH 1) 的抑制剂，其对R132H、HT1080 和U87R132H细胞中的突变型IDH 1 的IC50 值 ≤ 0.5 μM。

Mutant IDH1-IN-4

Mutant IDH1-IN-4 Chemical Structure

CAS No. : 1416270-18-2

规格 价格 是否有货 数量
5 mg ￥8500 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Mutant IDH1-IN-4 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus

生物活性

Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells[1].

IC50 & Target

IC50: ≤ 0.5 μM (mutant IDH 1 in cells)[1].
分子量

438.56

Formula

C25H34N4O3
CAS 号

1416270-18-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. US20170210749A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant EGFR inhibitor

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant EGFR inhibitor  纯度: 99.10%

Mutant EGFR inhibitor是有效，选择性的 EGFR 突变体抑制剂，来自专利WO 2013014448 A1；可抑制EGFRL858R，EGFRExon 19 deletion，EGFRT790M。

Mutant EGFR inhibitor

Mutant EGFR inhibitor Chemical Structure

CAS No. : 1421373-62-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥2170 In-stock
5 mg ￥1900 In-stock
10 mg ￥2800 In-stock
50 mg ￥8500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Mutant EGFR inhibitor 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Differentiation Inducing Compound Library
  • Anti-Hepatitis C Virus Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Targeted Diversity Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1; inhibits EGFRL858R, EGFRExon 19 deletion and EGFRT790M.

IC50 & Target

EGFRL858R

 

EGFRExon 19 deletion

 

EGFRT790M

 

分子量

520.03

Formula

C27H30ClN7O2
CAS 号

1421373-62-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 50 mg/mL (96.15 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9230 mL 9.6148 mL 19.2297 mL
5 mM 0.3846 mL 1.9230 mL 3.8459 mL
10 mM 0.1923 mL 0.9615 mL 1.9230 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.81 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.81 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. WO 2013014448 A1

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

KRAS mutant protein inhibitor 1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KRAS mutant protein inhibitor 1 

KRAS mutant protein inhibitor 1 是一种用于癌症潜在治疗的 KRAS 突变蛋白抑制剂。

KRAS mutant protein inhibitor 1

KRAS mutant protein inhibitor 1 Chemical Structure

CAS No. : 2642305-16-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential treatment in cancer.

分子量

654.95

Formula

C31H27Cl3FN7O2
CAS 号

2642305-16-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kargbo RB. Targeting KRAS Mutant Protein Inhibitor for Potential Treatment in Cancer. ACS Med Chem Lett. 2021 Oct 7;12(11):1633-1634.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

RAF mutant-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

RAF mutant-IN-1 

RAF mutant-IN-1 是RAF kinase 的抑制剂，信息来自专利WO2019107987A1，对C-RAF 340D/Y341D、B-RAFV600E 和B-RAFWT 的IC50 值分别为 21 nM、30 nM和392 nM。

RAF mutant-IN-1

RAF mutant-IN-1 Chemical Structure

CAS No. : 2340020-82-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively[1].

IC50 & Target

C-RAF 340D/Y341D

21 nM (IC50)

B-RafV600E

30 nM (IC50)

BRAFWT

392 nM (IC50)

分子量

567.85

Formula

C23H18Cl3FN6O2S
CAS 号

2340020-82-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. BAE, In Hwan, et al. Title of Invention: THIENO[3,2-d]PYRIMIDINE COMPOUND HA VING INHIBITORY ACTIVITY FOR PROTEIN KINASE. WO2019107987A1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

EGFR mutant-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

EGFR mutant-IN-1 

EGFR mutant-IN-1 是一种 5-甲基嘧啶吡啶酮衍生物，是有效的，选择性 EGFRL858R/T790M/C797S 突变抑制剂，IC50 为 27.5 nM，对 EGFRWT 的抑制作用明显较低 (IC50 >1.0 μM)。

EGFR mutant-IN-1

EGFR mutant-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFRL858R/T790M/C797S mutant inhibitor with an IC50 of 27.5 nM, while being a significantly less potent for EGFRWT (IC50 >1.0 μM)[1].

IC50 & Target

IC50: 27.5 nM (EGFRL858R/T790M/C797S) and >1.0 μM (EGFRWT)[1]
分子量

632.17

Formula

C34H39ClFN7O2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Shen J, et al. Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type SparingInhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S). J Med Chem. 2019 Aug 8;62(15):7302-7308.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mutant IDH1-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mutant IDH1-IN-1  纯度: 99.53%

Mutant IDH1-IN-1是 IDH1 突变体的选择性抑制剂，对突变体IDH1 R132C/R132C，IDH1 R132H/R132H，IDH1 R132H/WT和野生型IDH1的 IC50 值分别为4, 42, 80 和 143 nM。

Mutant IDH1-IN-1

Mutant IDH1-IN-1 Chemical Structure

CAS No. : 1355326-21-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥3839 In-stock
2 mg ￥2333 In-stock
5 mg ￥3500 In-stock
10 mg ￥5000 In-stock
50 mg ￥15000 In-stock
100 mg ￥21000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Mutant IDH1-IN-1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Mitochondria-Targeted Compound Library
  • Glucose Metabolism Compound Library

生物活性

Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.

IC50 & Target

IC50: 4 nM (IDH1 R132C/R132C), 42 nM (IDH1 R132H/R132H), 80 nM (IDH1 R132H/WT), 143 nM (IDH1 wild type)[1]
分子量

498.59

Formula

C30H31FN4O2
CAS 号

1355326-21-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 45 mg/mL (90.25 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.0057 mL 10.0283 mL 20.0566 mL
5 mM 0.4011 mL 2.0057 mL 4.0113 mL
10 mM 0.2006 mL 1.0028 mL 2.0057 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Deng G, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem. 2015 Jan 9;290(2):762-74.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务